Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–93 of 93 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Valvular Diseases Clear all

Conditions: Non-valvular Atrial Fibrillation, Stroke, Systemic Embolism
Interventions: Experimental: Laminar Left Atrial Appendage Closure System, Active Comparator: WATCHMAN / Amulet; Device
Lead sponsor: Jaguar LAA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more

Conditions: Valve Disease, Aortic, Mitral Regurgitation (MR), Aortic Stenosis, Valvular Heart Disease, Tricuspid Regurgitation (TR), Aortic Regurgitation
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Mitral Regurgitation, Tricuspid Regurgitation, Valvular Heart Disease
Interventions: Abbott SJM Rigid Saddle Ring, Abbott SJM Séguin Ring, Abbott SJM Tailor Ring, Abbott SJM Tailor Band; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 2
States / cities: Durham, North Carolina • Madison, Wisconsin

Conditions: Disparities in Treatment of Aortic Valve Stenosis, Aortic Valve Stenosis
Interventions: Patient Questionnaire, Provider Questionnaire; Other
Lead sponsor: Minneapolis Heart Institute Foundation; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Atrial Fibrillation
Interventions: Rivaroxaban (Xarelto, BAY59-7939), VKA (Vitamin K antagonist); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 38,831 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Atrial Fibrillation
Interventions: Dabigatran (Pradaxa), Vitamin K antagonist; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 56,039 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Atrial Fibrillation
Interventions: pantoprazole, Pradaxa (dabigatran etexilate), Pradaxa, within 30 minutes after a meal; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,067 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 81
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more

Conditions: Coronary Artery Disease, Myocardial Ischemia, Coronary Disease, Heart Diseases, Valvular Heart Disease
Interventions: Custodiol HTK, Cold Blood Cardioplegia; Drug
Lead sponsor: Marc Sakwa, MD; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Heart Valve Diseases
Interventions: cardiac echosonography; Device
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Critical Aortic Stenosis
Interventions: Edwards SAPIEN Transcatheter Heart Valve, Surgical Valve Replacement, medical management and/or balloon aortic valvuloplasty; Device · Other
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: Not listed
Enrollment: 1,057 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 22
States / cities: La Jolla, California • Los Angeles, California • Stanford, California + 17 more

Conditions: Atrial Fibrillation
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 21
States / cities: Pasadena, California • Coral Springs, Florida • Port Charlotte, Florida + 18 more

Conditions: Atrial Fibrillation, Percutaneous Coronary Intervention
Interventions: Dabigatran Etexilate 110mg, Warfarin 3mg, Aspirin, Dabigatran Etexilate 150mg, Clopidogrel or Ticagrelor, Warfarin 5mg, Warfarin 1mg; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 2,725 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 45
States / cities: Birmingham, Alabama • Cottonwood, Arizona • Mesa, Arizona + 41 more

Conditions: Valvular Heart Disease, Pericardial Disease, Cardiomyopathies
Interventions: Photoplethysmography; Diagnostic Test
Lead sponsor: Tulane University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: New Orleans, Louisiana

Conditions: Valvular Heart Disease
Interventions: HBCR hands-off, HBCR interactive; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure, HFrEF - Heart Failure with Reduced Ejection Fraction, HFpEF - Heart Failure with Preserved Ejection Fraction, Syncopation, Syncope, Ischemic Cardiovascular Disease, STEMI, STEMI (ST Elevation MI), Atrial Fibrillation (AF), Atrial Enlargement, LVF, Conduction Defect, Conduction Abnormalities, Heart Block, Valvular Diseases, Cardiac Output, Low, Stroke Volume, Stroke Volume Variation, Hyperkalemia, Hypercalcemia, Hypocalcemia, LV Dysfunction, QT Prolongation, Sudden Cardiac Death Due to Cardiac Arrhythmia, Ventricular Arrhythmia, Pacing, Pacing Induced Dyssynchrony, Silent Ischemia, Pericarditis, Sleep Related Breathing Disorder, RSA, Apnea, Obstructive, Cardiac Output Measurement, Respiratory Impedance, CRT And/or ICD, Infarction, Cardiomyopathies, Primary, Hypertrophy
Interventions: SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C, SUBPROTOCOL D, SUBPROTOCOL E, SUBPROTOCOL F, SUBPROTOCOL G, SUBPROTOCOL H; Device
Lead sponsor: Peerbridge Health, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 15,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Melbourne, Florida

Conditions: Valvular Heart Disease
Interventions: Not listed
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 330,570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Atrial Fibrillation
Interventions: betrixaban, Warfarin; Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 19
States / cities: Anaheim, California • Colorado Springs, Colorado • Melbourne, Florida + 16 more

Conditions: Atrial Fibrillation
Interventions: Not listed
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 25,586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Lexington, Massachusetts

Conditions: Atrial Fibrillation, Thromboembolism
Interventions: Edoxaban (DU-176b), warfarin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 22
States / cities: Huntsville, Alabama • Anaheim, California • Beverly Hills, California + 19 more

Conditions: Mitral Regurgitation, Valvular Heart Disease, Heart Failure
Interventions: MitraClip, Moderate MR; Device · Other
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years to 99 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Atrial Fibrillation
Interventions: WATCHMAN FLX; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 29
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 24 more

Search by objective public record fields.

A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination

DELINEATE-Prospective

Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study

Racial and Economic Disparities and Unmet Needs in Patients With Severe Aortic Valvular Disease

Real-world Comparative Effectiveness of Rivaroxaban Versus VKA

Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent

Methods Study to Evaluate Use of Cardiac Ultrasound to Assess Heart Valve Abnormality in People.

THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial

Eliminate Thromboembolism: Improving Anticoagulation in Non-valvular Atrial Fibrillation Patients

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

PPG to Predict Ejection Fraction and Other Echographic Data in the General Population

Home-Based Cardiac Rehabilitation Using a Novel Mobile Health Exercise Regimen Following Transcatheter Heart Valve Interventions

COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable

The Bronx-Valve Registry

Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin

The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage

A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation

In Search of Best Practices for Patients With Heart Failure and Secondary Mitral Regurgitation: An Evaluation of the Inova Heart Failure Treatment Algorithm

Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology